Should I buy Elevance Health stock in 2025?
Is Elevance Health stock a buy right now?
As of early May 2025, Elevance Health (NYSE: ELV) is trading around $408, with a recent average daily trading volume of approximately 1.68 million shares. The healthcare plans leader has demonstrated notable resilience despite sector volatility and regulatory headwinds: its Q1 2025 results revealed operating revenue growth of 15.4% year-over-year, supported by robust performance in both the Health Benefits and Carelon segments. The company returned $1.3 billion to shareholders last quarter through dividends and share repurchases—underlining management’s commitment to capital returns. While recent Department of Justice lawsuits against major Medicare insurers spark some uncertainty, the market sentiment remains constructive, buoyed by continued membership growth and sector-wide demand for whole-health solutions and personalized digital care. The current P/E ratio of 15.9 appears reasonable against the company’s growth profile and relative stability (beta 0.78), core differentiators amid broader market swings. Notably, analyst consensus from over 33 national and international banks sets a target price at $531, pointing toward substantial upside as confidence grows in Elevance’s capacity to expand and adapt. With the healthcare sector focusing increasingly on innovation and efficiency, Elevance Health stands as a key player for investors considering strategic exposure.
- Double-digit revenue growth driven by both Health Benefits and Carelon segments.
- Consistent dividend payments with a current yield of 1.68%.
- Diversified business model spanning pharmacy, home health, and risk-based services.
- Low volatility profile with a 5-year beta of 0.78.
- Significant capital return strategy through buybacks and growing dividends.
- Ongoing regulatory scrutiny introduces some near-term operational uncertainty.
- Recent underperformance over 12 months compared to sector peers.
- What is Elevance Health?
- How much is Elevance Health stock?
- Our full analysis on Elevance Health </b>stock
- How to buy Elevance Health stock in United States?
- Our 7 tips for buying Elevance Health stock
- The latest news about Elevance Health
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the performance of Elevance Health for over three years. Every month, hundreds of thousands of users in the United States rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not serve as investment advice. In line with our ethical guidelines, we have never been, and will never be, compensated by Elevance Health.
What is Elevance Health?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | U.S.-headquartered, benefiting from the world's largest healthcare market. |
| 💼 Market | NYSE (New York Stock Exchange) | Highly liquid; large-cap U.S. healthcare stock with broad investor access. |
| 🏛️ ISIN code | US0367521038 | Standard unique code enables transparent international trading. |
| 👤 CEO | Gail K. Boudreaux | CEO since 2017; recognized for driving expansion and diversification. |
| 🏢 Market cap | $92.25 billion | Large-cap status indicates significant financial and strategic resources. |
| 📈 Revenue | $48.8 billion (Q1 2025) | Double-digit year-over-year revenue growth demonstrates operational strength. |
| 💹 EBITDA | $3.3 billion (Q1 2025, adjusted op gain) | Solid profit generation; margin pressure noted in Health Benefits segment. |
| 📊 P/E Ratio (Price/Earnings) | 15.90 (TTM); Forward: 11.83 | Attractive valuation with room for upside; forward P/E suggests expected earnings growth. |
How much is Elevance Health stock?
The price of Elevance Health stock is falling this week. As of now, ELV trades at $408.31, down 2.92% over the past 24 hours and showing a 4.78% drop this week. The company holds a market capitalization of $92.25 billion, with an average three-month trading volume of about 1.68 million shares. Elevance Health currently features a P/E ratio of 15.90, provides a dividend yield of 1.68%, and carries a stock beta of 0.78—indicating lower volatility than the broader market. Investors should note that, despite recent price weakness, Elevance Health offers a blend of income and defensive sector characteristics in today’s market.
Check out the USA's best brokers!Compare brokersOur full analysis on Elevance Health stock
We have conducted a rigorous review of Elevance Health, Inc.’s most recent financial performance and assessed its stock trajectory over the past three years, leveraging a broad spectrum of financial indicators, technical signals, and sector-wide data, all integrated through our proprietary analytical algorithms. Our approach provides a comprehensive perspective that accounts for both recent events and longer-term trends, comparing Elevance Health not only to its historical self but also against its main industry competitors. So, why might Elevance Health stock once again become a strategic entry point into the U.S. healthcare sector in 2025?
Recent Performance and Market Context
Despite the challenging environment facing U.S. healthcare insurers, Elevance Health (NYSE: ELV) has demonstrated significant resilience and strategic agility. Currently priced at $408.31—a YTD gain of 10.68%—the stock, nevertheless, reflects a cautious sentiment, retreating -22.20% over the past twelve months and closing notably beneath this year’s $567.26 peak and last year’s levels. Notably, recent performance over the last week has been softly negative (-4.78%), partly in reaction to sector-wide regulatory scrutiny and short-term technical pressure.
Yet beneath this surface volatility, several positive developments stand out. For Q1 2025, Elevance reported operating revenue of $48.8 billion, representing a robust 15.4% year-over-year increase, with adjusted operating gains and earnings per share (EPS) both moving decisively higher. Additionally, the company returned $1.3 billion to shareholders during the quarter through share buybacks and dividend payments, signaling ongoing confidence in both its liquidity position and future cash flow generation.
The broader healthcare landscape offers a highly favorable backdrop as the sector pivots toward value-based care and digital health solutions. Across the market, investors are increasingly seeking stocks that combine defensiveness with innovation—a space where Elevance, with its diversified model and leadership in both insurance and care delivery, is strongly positioned.
Technical Analysis
Recent price action underscores a market still searching for a bottom, but also establishing the foundation for a potential reversal. At $408.31, ELV trades below its 9-, 18-, and 40-day moving averages ($418.70, $425.74, and $426.50, respectively), suggesting short-term weakness but also raising the prospect of mean-reversion for technically oriented investors.
A closer look at technical indicators reveals several compelling signals:
- Relative Strength Index (14-day): Hovering between 30 and 50, ELV currently exhibits neutral momentum, neither oversold nor overbought—historically, such readings have preceded upward inflections when paired with improving fundamentals.
- MACD (3-10-16): The average at $440.68, which sits well above the spot price, points toward latent upside should buyer interest return.
- Support Levels: Strong technical bases are found at $404.49 and $400.66, offering what appears to be resilient near-term floors.
- Resistance Zones: First resistance stands at $415.76, while a break through $423.21 would open the way for a more substantial bullish phase, particularly if coupled with rising volume.
Collectively, although near-term technicals are neutral to bearish, multiple layers of support and constructive longer-term momentum structures indicate that current levels may represent an attractive entry for investors anticipating a sectoral rebound or next earnings-driven catalyst.
Fundamental Analysis
On a fundamental basis, Elevance Health’s strengths are increasingly apparent as the company executes against its multi-year growth strategy. Q1 2025 results revealed:
- Revenue Growth: Total operating revenue surged 15.4% YoY to $48.8 billion—well above industry averages, fuelled by both organic expansion and strategic acquisitions.
- Earnings Power: Adjusted EPS delivered notable 10.5% annual growth, reaching $11.97, and diluted EPS for the quarter was $9.61.
- Profitability & Expense Control: The operating expense ratio improved by 70 basis points YoY to 10.9%, even as the benefit expense ratio rose slightly. This highlights success in cost optimization and operational efficiency—a key margin driver in a competitive marketplace.
Valuation metrics reinforce the thesis. A TTM P/E of 15.90 and forward P/E of 11.83 position ELV favorably relative to both historical norms and major competitors, especially when factoring in the compelling PEG ratio of 0.74—suggestive of growth that outpaces its current market multiple. The price/book ratio of 2.17 and an attractive dividend yield of 1.68% (supported by consistent annual increases) add further ballast for those seeking quality recurring income with growth optionality.
Structurally, Elevance Health benefits from:
- Leadership in both traditional health plans and innovative healthcare services via Carelon,
- Expanding market share in Medicare Advantage and individual ACA plans,
- A well-regarded brand, robust balance sheet, and stable, experienced executive leadership,
- Diversification via pharmacy services and home health, which lessens risk tied to any single health benefits segment.
Volume and Liquidity
Market liquidity remains a driving strength. With an average daily volume of 1.67 million shares (3-month average), Elevance Health attracts a broad mix of institutional and retail participants, bolstering price discovery and reducing bid-ask spreads.
The float—underpinned by major institutional shareholders (notably Vanguard and BlackRock with a combined stake over 15%)—further supports valuation dynamism, while also minimizing potential for illiquidity-related drawdowns during periods of sector volatility.
Sustained trading volume at current levels suggests that investor confidence in the equity story remains high, especially given the stock’s ability to rapidly absorb both macroeconomic headwinds and sector-specific uncertainties.
Catalysts and Positive Outlook
A raft of potential catalysts stands poised to support renewed upside in the latter half of 2025:
- Expansion in Growth Verticals: Strong growth in Medicare Advantage, Individual ACA plan membership, and Carelon (up 38% YoY) should continue to drive revenue and margin expansion.
- Acquisitions & Innovation: Recent additions in home health and pharmacy services are already accretive, with further M&A and internal innovation likely as Elevance scales digital and risk-based care models.
- ESG and Whole-Health Initiatives: Accelerating its pivot towards personalized, digital-first, value-based care models, Elevance is capitalizing on industry trends that align closely with evolving regulatory incentives and consumer preferences.
- Capital Return: A remaining $8.4 billion of Board authorization for share buybacks enables opportunistic repurchases and drives EPS accretion.
- Guidance: Management’s reaffirmed FY 2025 adjusted EPS guidance ($34.15–$34.85) signals earnings stability and visibility even amidst sectoral turbulence.
The market consensus price target of $505.55, representing a 24% premium to current levels, further underlines the optimistic outlook held by analysts. Should the legal clouds over the sector dissipate or be resolved favorably, sentiment could improve rapidly and spark a rerating of the stock.
Investment Strategies
Elevance Health’s current technical and fundamental configuration offers multiple points of entry depending on investment horizon and risk appetite:
- Short-Term: Opportunistic buyers could benefit from entering near strong support zones ($404.49/$400.66)—especially if signs of upward momentum or improving sector sentiment emerge. A near-term swing towards first resistance ($415.76) could offer attractive upside.
- Medium-Term: Reacceleration of EBITDA growth in Q2/Q3, positive regulatory news, or delivery of further earnings beats could act as triggers for price normalization back to the $450–$480 range.
- Long-Term: For those seeking core healthcare exposure, current valuations offer a compelling position ahead of continued sectoral digitalization, demographic tailwinds, and ongoing cost/revenue synergies. The stock’s low beta (0.78) enhances its appeal as a diversification tool within portfolios sensitive to broad market volatility.
Positioning at current levels, just above key technical supports and ahead of likely medium-term catalysts, appears well justified based on both historical valuation analysis and improving forward multiples.
Is it the Right Time to Buy Elevance Health?
Summing up, Elevance Health exhibits a unique combination of strong top-line growth, disciplined expense management, attractive shareholder returns, and forward-looking strategic investments. Operational execution continues to beat sector averages, while the stock’s current valuation (forward P/E of 11.83, PEG at 0.74) appears increasingly difficult to ignore, especially in light of a 24% price target premium posited by Wall Street consensus.
Crucially, recent underperformance offers what seems to be a rare window to establish or expand positions at a material discount to intrinsic value—while also benefiting from a secure dividend stream and substantial scope for multiple expansion as near-term uncertainties resolve. For investors favoring high-quality, resilient sector leaders with a clear roadmap for growth and innovation, Elevance Health seems to represent an excellent opportunity to capitalize on both current mispricing and long-term industry megatrends.
With macroeconomic tailwinds, firm fundamentals, and tangible catalysts on the horizon, Elevance Health is positioned to not only recover lost ground, but also to outperform as the healthcare sector evolves. For discerning investors seeking strong, risk-adjusted returns, Elevance Health stands out as a compelling consideration in any forward-looking portfolio poised for 2025 and beyond.
How to buy Elevance Health stock in United States?
Buying Elevance Health (ELV) stock online is straightforward and secure when you use a regulated U.S. broker. Investors can choose between buying actual shares (spot buying) or trading Contracts for Difference (CFDs), depending on their goals and risk tolerance. Spot buying means you own the shares, while CFDs let you speculate on price movements with leverage, but without ownership. Both methods provide easy access through modern trading platforms. For a detailed broker comparison, including fees and account features, please refer to the list further down this page.
Spot Buying
A cash or spot purchase means you buy actual Elevance Health shares on the NYSE, becoming a direct shareholder. Most U.S. online brokers charge a fixed commission per trade—typically around $5 per transaction. For example, if Elevance Health is trading at $408.31 per share, a $1,000 investment (after a $5 commission) lets you purchase about 2 shares.
Gain scenario example
Gain scenario: If the share price rises by 10% to $449.14, your holdings would be worth $1,100.
Result: That’s a $100 gross gain, or +10% on your original investment.
Trading via CFD
CFD (Contract for Difference) trading allows you to speculate on Elevance Health’s price movements without actually owning the stock. CFD brokers earn through the spread (the difference between buy and sell prices), and you may incur overnight financing costs for leveraged positions held longer than a day. For instance, with $1,000 and 5x leverage, you control a position worth $5,000.
Gain scenario example
Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 outlay (excluding fees), showing how leverage can amplify both returns and risks.
Final Advice
Before investing, always compare the fees, trading conditions, and platform features of different brokers to find the best fit for your strategy. The right method—spot buying or CFD trading—will depend on your specific investment goals, time horizon, and risk appetite. Ready to take the next step? Check out our broker comparison further down the page to begin your Elevance Health investment journey confidently.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the AMF in France, as well as the FCA (UK), ASIC (Australia) and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognized for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5. In the event that you remain inactive for 12 months or more, a $10 monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step-by-step, ensuring you have permanent access to your funds. After analyzing thousands of customer cases, no such problem has been identified.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is it easy to withdraw money from IG?
Withdrawing funds from IG is quick and straightforward, offering options such as PayPal, bank transfer, or credit card. Processing times are usually 1 to 3 business days. IG ensures a transparent withdrawal process, and many users appreciate the clarity of withdrawal fees, providing a hassle-free experience.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, starting with the AMF in France, but also the Central Bank of Ireland, ASIC (Australia) and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, wire transfer or electronic wallets. Everything is designed to offer you fast, clear and secure access.
Our 7 tips for buying Elevance Health stock
| Step | Specific tip for Elevance Health |
|---|---|
| Analyze the market | Review Elevance Health's financial performance, strong revenue growth, dividend consistency, and current regulatory challenges to understand both potential and risks before investing. |
| Choose the right trading platform | Pick a reputable U.S. broker that provides competitive commissions and direct access to NYSE, ensuring you can efficiently trade Elevance Health shares in regular market hours. |
| Define your investment budget | Allocate only a portion of your portfolio to Elevance Health, considering its moderate volatility and recent sector-specific risks; maintain diversification for balanced risk. |
| Choose a strategy (short or long term) | Favor a medium to long-term investment outlook, focusing on Elevance Health’s strategic growth in healthcare services, consistent dividends, and potential price recovery. |
| Monitor news and financial results | Stay updated on Elevance Health’s quarterly earnings, Medicare developments, legal proceedings, and industry trends, as these can impact stock performance and sentiment. |
| Use risk management tools | Set stop-loss or limit orders to manage downside risk, especially given recent price underperformance and potential for near-term volatility from regulatory issues. |
| Sell at the right time | Consider selling when Elevance Health approaches analyst target prices, shows signs of overbought conditions, or before major news that could trigger substantial volatility. |
The latest news about Elevance Health
Elevance Health reported robust Q1 2025 financial results, highlighted by a 15.4% year-over-year increase in revenue. Operating revenue reached $48.8 billion, and the company's adjusted diluted EPS grew to $11.97, up 10.5% compared to the same quarter last year. The Carelon segment stood out with 38% growth in revenue and a 34% increase in operating gain, signaling effective diversification and growth in healthcare services beyond traditional insurance. These strong top- and bottom-line results reaffirm Elevance Health's momentum in both core and emerging areas of its business.
The company reaffirmed its full-year 2025 earnings guidance and maintained a growing dividend trajectory. Elevance continues to project an adjusted diluted EPS of $34.15 to $34.85 for 2025 and recently declared a second quarter dividend of $1.71 per share, payable in June. The board’s commitment to shareholder returns is further highlighted by $880 million in Q1 share repurchases and over $8 billion remaining in buyback authorization, supporting both income investors and total return strategies.
Membership growth and expansion in key plan segments remain evident, especially in Medicare Advantage and ACA plans. Total medical membership as of March 31, 2025, increased by 99,000 since year-end, reflecting strong national demand for Elevance’s products. Expansion into government-backed plans, individual market solutions, and recent acquisitions in home health and pharmacy services confirm the company’s active growth strategy and deepening U.S. healthcare market footprint.
Analyst sentiment remains positive, with a consensus target price implying significant upside potential. Despite recent share price volatility and underperformance versus the broader market, analysts maintain an average price target of $505.55—representing an approximate 24% upside from current trading levels. The company’s comparatively low price-to-earnings ratio, solid PEG ratio, and low beta underscore an attractively valued, lower-risk opportunity given the scale and stability of its U.S. healthcare operations.
Elevance Health’s diversified business model and innovation in digital and value-based care continue to be well-received amid industry trends. The company’s focus on whole-health models, real-time digital support, and risk-based capabilities position it to meet evolving patient and payer needs in the U.S. By leveraging its Carelon platform for pharmacy, behavioral, and complex care services, Elevance is generating new sources of growth while supporting improved outcomes and cost control for members nationwide, reinforcing constructive market signals for long-term investors.
FAQ
What is the latest dividend for Elevance Health stock?
Elevance Health currently pays a quarterly dividend. The most recent declared dividend is $1.71 per share, payable on June 25, 2025. This brings the annualized dividend to $6.84 per share, with a yield of about 1.68% at current prices. Over recent years, Elevance Health has shown a pattern of consistent dividend increases, reflecting its stable cash flows and shareholder-friendly distribution policy.
What is the forecast for Elevance Health stock in 2025, 2026, and 2027?
Based on the current share price of $408.31, the projected price for the end of 2025 is $531, for 2026 is $613, and for 2027 is $817. These optimistic yet reasonable projections align with strong sector trends and analyst confidence in Elevance Health’s earnings growth, innovative expansion into pharmacy and home health, and robust fundamentals that position it well for the coming years.
Should I sell my Elevance Health shares?
Given Elevance Health's resilient business model, consistent dividend growth, and diversified presence in healthcare, holding onto the shares could be a sound strategy for the medium to long term. Despite some near-term volatility and regulatory challenges, the company’s current valuation remains attractive, and analyst targets suggest substantial upside potential. Investors focusing on stable income and healthcare sector exposure may find the company’s fundamentals supportive of a hold approach.
How are dividends from Elevance Health stock taxed in the United States?
Dividends paid by Elevance Health to U.S. investors are typically classified as qualified dividends, subject to favorable federal tax rates similar to long-term capital gains. U.S. shareholders do not face withholding tax on domestic dividends, and these may be included in tax-advantaged accounts like IRAs or 401(k)s, where taxes can be deferred or avoided altogether—enhancing the after-tax benefit for eligible investors.
What is the latest dividend for Elevance Health stock?
Elevance Health currently pays a quarterly dividend. The most recent declared dividend is $1.71 per share, payable on June 25, 2025. This brings the annualized dividend to $6.84 per share, with a yield of about 1.68% at current prices. Over recent years, Elevance Health has shown a pattern of consistent dividend increases, reflecting its stable cash flows and shareholder-friendly distribution policy.
What is the forecast for Elevance Health stock in 2025, 2026, and 2027?
Based on the current share price of $408.31, the projected price for the end of 2025 is $531, for 2026 is $613, and for 2027 is $817. These optimistic yet reasonable projections align with strong sector trends and analyst confidence in Elevance Health’s earnings growth, innovative expansion into pharmacy and home health, and robust fundamentals that position it well for the coming years.
Should I sell my Elevance Health shares?
Given Elevance Health's resilient business model, consistent dividend growth, and diversified presence in healthcare, holding onto the shares could be a sound strategy for the medium to long term. Despite some near-term volatility and regulatory challenges, the company’s current valuation remains attractive, and analyst targets suggest substantial upside potential. Investors focusing on stable income and healthcare sector exposure may find the company’s fundamentals supportive of a hold approach.
How are dividends from Elevance Health stock taxed in the United States?
Dividends paid by Elevance Health to U.S. investors are typically classified as qualified dividends, subject to favorable federal tax rates similar to long-term capital gains. U.S. shareholders do not face withholding tax on domestic dividends, and these may be included in tax-advantaged accounts like IRAs or 401(k)s, where taxes can be deferred or avoided altogether—enhancing the after-tax benefit for eligible investors.
